Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation.

Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J (2008) 1.29

Outcome Predictors for Pediatric Dilated Cardiomyopathy: A Systematic Review. Prog Pediatr Cardiol (2007) 1.14

Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy. Circ Heart Fail (2014) 0.95

Rbm20-deficient cardiogenesis reveals early disruption of RNA processing and sarcomere remodeling establishing a developmental etiology for dilated cardiomyopathy. Hum Mol Genet (2014) 0.89

Early predictors of survival to and after heart transplantation in children with dilated cardiomyopathy. Circulation (2012) 0.88

Outcome of pediatric patients with dilated cardiomyopathy listed for transplant: a multi-institutional study. J Heart Lung Transplant (2009) 0.85

Predictors of disease progression in pediatric dilated cardiomyopathy. Circ Heart Fail (2013) 0.84

Focal myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in children and adolescents with dilated cardiomyopathy. J Cardiovasc Magn Reson (2015) 0.82

Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies. Future Cardiol (2013) 0.79

Epidemiology and cost of heart failure in children. Cardiol Young (2015) 0.78

The impact of heart failure severity at time of listing for cardiac transplantation on survival in pediatric cardiomyopathy. J Heart Lung Transplant (2011) 0.77

Study of peripheral stem cells mobilization as a treatment line of pediatric dilated cardiomyopathy. Stem Cell Investig (2015) 0.75

Dilated cardiomyopathy of unknown cause in young patients: risk evaluation, possible etiologies, and treatment. Libyan J Med (2007) 0.75

Improved outcomes of pediatric dilated cardiomyopathy and heart transplantation. J Am Coll Cardiol (2005) 0.75

Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient-Derived iPSC Model. Clin Transl Sci (2016) 0.75

Cardiomyopathies: Treating pediatric DCM--great expectations unfulfilled. Nat Rev Cardiol (2010) 0.75

The efficacy of mitral valve surgery in children with dilated cardiomyopathy and severe mitral regurgitation. Pediatr Cardiol (2007) 0.75

An Alternative Strategy for Bridge-to-Transplant/Recovery in Small Children with Dilated Cardiomyopathy. Pediatr Cardiol (2017) 0.75

Outcomes of plasma exchange for severe dilated cardiomyopathy in children. Heart Vessels (2016) 0.75

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 50.94

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95

Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32

The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43

Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation (2006) 9.44

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 7.99

Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation (2010) 6.71

Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med (2007) 6.22

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet (2015) 6.13

Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol (1985) (2004) 5.29

Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med (2014) 5.11

An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm (2009) 4.99

Maternal age and other predictors of newborn blood pressure. J Pediatr (2004) 4.78

Prospective trial of a pediatric ventricular assist device. N Engl J Med (2012) 4.72

Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA (2006) 4.51

Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol (2003) 4.51

HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm (2011) 4.31

Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA (2007) 4.27

Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J (2010) 4.13

Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res (2005) 3.99

Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr (2010) 3.96

Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation (2002) 3.76

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol (2011) 3.57

Association between congenital cardiovascular malformations and neuroblastoma. J Pediatr (2004) 3.55

Clinical characterization of left ventricular noncompaction in children: a relatively common form of cardiomyopathy. Circulation (2003) 3.54

Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline. J Card Fail (2009) 3.54

Health effects of energy drinks on children, adolescents, and young adults. Pediatrics (2011) 3.52

Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation (2006) 3.50

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med (2004) 3.50

Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med (2010) 3.42

The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med (2003) 3.28

Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol (2003) 3.20

Desmosomal dysfunction due to mutations in desmoplakin causes arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Res (2006) 2.95

Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet (2002) 2.95

Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93

Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study. J Am Coll Cardiol (2008) 2.91

Noninvasive detection of cuprizone induced axonal damage and demyelination in the mouse corpus callosum. Magn Reson Med (2006) 2.90

2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.90

Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation (2007) 2.88

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 2.85

Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet (2013) 2.82

Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm (2009) 2.82

Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation (2007) 2.76

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol (2010) 2.74

Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Mol Genet Metab (2005) 2.72

Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation (2006) 2.69

Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol (2004) 2.68

Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol (2009) 2.65

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood (2006) 2.62

Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation (2005) 2.58

Beta2-adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation (2006) 2.57

HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace (2011) 2.54

2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.53

Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol Genet Metab (2003) 2.42

Systematic review and meta-analysis of circulatory disease from exposure to low-level ionizing radiation and estimates of potential population mortality risks. Environ Health Perspect (2012) 2.42

Mortality and sudden death in pediatric left ventricular noncompaction in a tertiary referral center. Circulation (2013) 2.41

Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg (2008) 2.40

Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation (2008) 2.40

Fetal aortic valve stenosis and the evolution of hypoplastic left heart syndrome: patient selection for fetal intervention. Circulation (2006) 2.35

Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians. J Am Coll Cardiol (2013) 2.34

Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation (2007) 2.33

An analysis of energy-drink toxicity in the National Poison Data System. Clin Toxicol (Phila) (2013) 2.31

A cross-sectional study of exercise performance during the first 2 decades of life after the Fontan operation. J Am Coll Cardiol (2008) 2.30

Dilated cardiomyopathy. Lancet (2010) 2.24

Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol (2003) 2.22

Spectrum of CHD7 mutations in 110 individuals with CHARGE syndrome and genotype-phenotype correlation. Am J Hum Genet (2005) 2.22

Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation (2002) 2.20

State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17

Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet (2002) 2.16

Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol (2011) 2.15

Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J (2007) 2.14

Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol (2009) 2.14

Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome. Ann Neurol (2002) 2.14

Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med (2008) 2.12

Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA (2006) 2.12

CCDC39 is required for assembly of inner dynein arms and the dynein regulatory complex and for normal ciliary motility in humans and dogs. Nat Genet (2010) 2.12

Nomenclature for congenital and paediatric cardiac disease: historical perspectives and The International Pediatric and Congenital Cardiac Code. Cardiol Young (2008) 2.10

Berlin Heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US children. Circulation (2013) 2.07

Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet (2002) 2.06

Quantification of increased cellularity during inflammatory demyelination. Brain (2011) 2.05